There is no treatment that eliminates HPV from your body, but there are effective treatments for every condition HPV causes, from genital warts to precancerous cells to cancer. The virus itself typically clears on its own: about 69% of HPV 16 infections and 85% of HPV 18 infections clear within two years, driven entirely by your immune system. What doctors treat are the problems HPV leaves behind when it doesn’t clear quickly enough.
Why There’s No Antiviral for HPV
Unlike infections such as herpes or HIV, HPV has no targeted antiviral medication. The CDC’s treatment guidelines are explicit: treatments exist for the conditions caused by HPV, not for the virus itself. Subclinical HPV infection, meaning you test positive but have no visible warts or abnormal cells, generally clears without intervention. By 48 months, over 82% of HPV 16 infections and 90% of HPV 18 infections resolve on their own.
This means that if you’ve tested positive for HPV but have normal screening results and no symptoms, your body is likely handling the infection already. Treatment enters the picture only when HPV causes something visible or detectable: warts, abnormal cervical cells, or cancer.
Treating Genital Warts
Genital warts are the most common reason people seek HPV treatment, and several options can remove them. None of these treatments “cure” the underlying HPV infection, but they eliminate the warts themselves. Your provider will recommend an approach based on the size, number, and location of the warts.
In-Office Procedures
Cryotherapy uses liquid nitrogen to freeze and destroy wart tissue. It’s one of the most common approaches. You’ll feel pain during and after the application, and blistering is normal. For large or widespread warts, local anesthesia helps. The procedure works best when performed by someone experienced, since freezing too much or too little tissue affects results.
Electrocautery burns warts away using an electrical current after the area is numbed. It’s precise and controls bleeding automatically, but requires careful technique to avoid scarring. For extensive warts or those that haven’t responded to other treatments, surgical removal or CO2 laser therapy can clear larger areas. These procedures typically reach only the upper layer of skin, and stitches are rarely needed.
Prescription Creams and Gels
Several topical medications can be applied at home. These work either by destroying wart tissue directly or by stimulating your immune system to fight the virus at the wart site. Your provider will walk you through the application schedule, which varies by medication. Side effects commonly include skin irritation, redness, and soreness at the treatment site.
Wart Recurrence Is Common
One of the most frustrating aspects of genital wart treatment is recurrence. Research published in The Journal of Infectious Diseases found that 44.3% of people experienced wart recurrence after their first episode, with some people having as many as 10 recurrent episodes over roughly four years of follow-up. This doesn’t mean treatment failed. It means the virus was still present in surrounding tissue and produced new warts. Recurrences tend to decrease over time as the immune system gains better control of the infection.
Treating Precancerous Cell Changes
When HPV persists, particularly high-risk strains like HPV 16 and 18, it can cause abnormal cell changes in the cervix. These precancerous changes are caught through routine screening and are highly treatable before they ever become cancer.
The most common procedure in the United States is called LEEP (loop electrosurgical excision procedure). A thin wire loop carrying an electrical current removes the abnormal tissue from the cervix. The key advantage of LEEP over older methods like cryotherapy is that it produces a tissue sample that can be examined under a microscope, confirming exactly what was removed. This makes it both a treatment and a diagnostic tool in one step.
Cold knife cone biopsy, which uses a scalpel to remove a cone-shaped section of cervical tissue, is another option, particularly when the abnormal area extends deeper into the cervical canal. Laser ablation destroys the tissue with heat but doesn’t produce a specimen for analysis, so it’s used less frequently now. LEEP has largely replaced older ablative techniques in the U.S. because of this diagnostic advantage. Excision is sometimes less effective when the abnormal area is very large, located high in the cervical canal, or extends deep into cervical tissue.
Treatment for HPV-Related Cancers
HPV causes several types of cancer, including cervical, throat, anal, and penile cancers. The treatment approach depends on the cancer’s type, stage, and location, but the general tools are surgery, radiation, and chemotherapy, sometimes in combination.
One important piece of context: HPV-positive cancers, particularly throat cancers, tend to respond better to treatment than HPV-negative versions of the same cancer. For HPV-positive oropharyngeal cancer in patients with a low-risk profile (minimal smoking history, limited spread), the three-year survival rate is 93%. Even for intermediate-risk patients, it’s about 71%. By comparison, high-risk HPV-negative throat cancers have a three-year survival rate closer to 46%.
Early-stage HPV-related throat cancers are typically treated with radiation or surgery alone. More advanced stages combine surgery with post-operative radiation, sometimes alongside chemotherapy. For HPV-positive cases specifically, radiation combined with a platinum-based chemotherapy drug remains the standard of care, after clinical trials showed it outperformed alternative drug combinations. In one major trial, the five-year overall survival rate for HPV-positive patients on this standard regimen was nearly 85%.
Cervical cancer treatment follows a similar framework: early-stage disease is often managed with surgery, while more advanced cases require radiation and chemotherapy. Immunotherapy has also become an option for recurrent or metastatic HPV-related cancers that don’t respond to initial treatment.
Screening Catches Problems Early
Because HPV-related conditions are so treatable when caught early, screening is one of the most important tools you have. Current guidelines recommend:
- Ages 21 to 29: Pap test every three years. HPV co-testing is not recommended before age 30.
- Ages 30 to 65: Primary HPV testing every five years (preferred), or co-testing with both an HPV test and Pap test every five years. If HPV testing isn’t available, a Pap test alone every three years is acceptable.
Average-risk individuals should not be screened more frequently than every three years. These intervals are designed to catch persistent infections and cell changes without overtreating infections that would resolve on their own.
Prevention Still Matters After Diagnosis
Even if you already have HPV, vaccination may still offer some benefit. The current vaccine protects against nine HPV strains and is recommended starting at age 9 through age 26. Adults between 27 and 45 who weren’t vaccinated earlier can discuss it with their provider. More than 15 years of real-world data confirm the vaccine provides long-lasting protection against HPV-related cancers.
For people who’ve already had genital warts, vaccination may reduce the chance of future episodes. In one trial, vaccinated women who had previously cleared genital warts had 46.8% fewer recurrences than those who received a placebo. When low-grade lesions of the vagina and vulva were included, the vaccine was associated with a statistically significant 60% reduction in new lesions caused by vaccine-targeted HPV types.
Therapeutic Vaccines in Development
A new class of vaccines is being developed to treat existing HPV infections rather than prevent new ones. As of late 2024, the World Health Organization tracked at least six candidates targeting active HPV infections, ten or more targeting precancerous lesions, and eight aimed at invasive cancer (all as part of combination therapy). Some of the precancer vaccines have shown modest but measurable success in shrinking abnormal cervical lesions and helping the body clear the virus. Modeling suggests that, under the most optimistic assumptions, therapeutic vaccines could prevent up to 25% of cervical cancer cases over 30 years. These vaccines face significant hurdles, including limited involvement from major pharmaceutical companies and funding challenges in lower-income countries, but several are in mid-to-late-stage clinical trials.